Global Head And Neck Cancer Therapeutics Market Report 2022: Sector to Reach $2.5 Billion by 2028 at a 12.3% CAGR

News provided by

Jan 12, 2023, 16:30 ET

DUBLIN, Jan. 12, 2023 /PRNewswire/ -- The "Global Head And Neck Cancer Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy Type (Immunotherapy, Chemotherapy, and Targeted Therapy), By Route of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

The Global Head And Neck Cancer Therapeutics Market size is expected to reach $2.5 billion by 2028, rising at a market growth of 12.3% CAGR during the forecast period.

Market Growth Factors

Increasing Demand For Immunotherapy Treatment

Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer. Some tumors respond well to conventional therapies such as chemotherapy. In other instances, immunotherapy is combined with conventional cancer therapies to increase the body's natural defenses against cancer. As part of its regular functionality, the immune system discovers and eliminates aberrant cells, so preventing or stifling the formation of several malignancies. Immune cells, for instance, are occasionally seen in and surrounding tumors.

Increasing Patient Population To Drive Market Growth

Head and neck cancers are classified according to their location. These regions include the oral cavity, pharynx, larynx, paranasal sinuses, and nasal cavity, as well as the salivary glands. An increase in alcohol and cigarette intake is a key cause of head and neck cancer. An estimated 75% of head and neck cancers are caused by alcohol and cigarette intake. Cancer will be the top cause of mortality, accounting for over 10 million fatalities, or one in six deaths.

Marketing Restraining Factor

Associated Side Effects Of Chemotherapy

Cancer of the head and neck are frequently treated with a mix of radiation and chemotherapy treatment. The adverse effects include hair loss, speech impairment, and loss of natural voice. In addition, after undergoing cancer surgery, people have difficulty eating. Although hair loss is a frequent side effect of chemotherapy, it does not affect everyone. Individuals can ask their care provider whether it is likely a medication side effect.

Therapy Type Outlook

Based on the Therapy Type, the Head and Neck Cancer Therapeutics Market is segmented into Chemotherapy, Immunotherapy, and Targeted Therapy. The immunotherapy segment acquired the highest revenue share in the head and neck therapeutics market in 2021. It is because immunotherapy make use of the immune system to treat cancer. Pembrolizumab, an anti-PD1 immunotherapy that targets cells with a deficiency in their capacity to repair DNA, may fall under this category.

Route of Administration Outlook

On the basis of the Route of Administration, the Head and Neck Cancer Therapeutics Market is divided into Injectable and Oral. The oral segment garnered a substantial revenue share in the head and neck cancer therapeutics market in 2021. Due to the rising number of oral medicinal medicines used to treat patients with Head and neck cancer. It is anticipated that the successful conclusion of the study and subsequent launch will stimulate segment growth. Patients with cancer are also administered oral chemotherapy.

Distribution Channel Outlook

By Distribution Channel, the Head and Neck Cancer Therapeutics Market is classified into Retail and Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. The retail and specialty pharmacies witnessed the highest segment revenue share in the head and neck cancer therapeutics market in 2021. It is because specialty pharmacies offer medications unavailable in conventional pharmacies, such as immunotherapy drugs. Providing these drugs through a specialty pharmacy guarantees their appropriate and secure delivery.

Regional Outlook

Region-wise, the Head and Neck Cancer Therapeutics Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment registered the largest revenue share in the head and neck cancer therapeutics market in 2021. It is due to the government assistance for the expansion of the healthcare sector, attractive reimbursement rules, a high level of illness awareness, and easy access to high-quality healthcare facilities are among the factors that have contributed to the expansion of the regional market.

Scope of the Study
By Therapy Type

Immunotherapy
Chemotherapy
Targeted Therapy

By Route of Administration

Injectable
Oral

By Distribution Channel

Retail & Specialty Pharmacies
Hospital Pharmacies
Online Pharmacies

By Geography

North America
US
Canada
Mexico
Rest of North America

Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Asia Pacific
China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific

LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA

Key Market Players
List of Companies Profiled in the Report:

Eli Lilly and Company
Merck & Co., Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceuticals Industries Ltd.
F. Hoffmann-La Roche Ltd.
AstraZeneca Plc
Bristol Myers Squibb Company
Clinigen Group PLC

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Strategies Deployed in Head And Neck Cancer Therapeutics Market

Chapter 4. Global Head & Neck Cancer Therapeutics Market by Therapy Type

Chapter 5. Global Head & Neck Cancer Therapeutics Market by Route of Administration

Chapter 6. Global Head & Neck Cancer Therapeutics Market by Distribution Channel

Chapter 7. Global Head & Neck Cancer Therapeutics Market by Region

Chapter 8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/jt4iix

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets